2018 Preliminary Program

PRELIMINARY PROGRAM
Working titles/topics shown. Final titles and speakers will follow
EDUCATIONAL SESSIONS

Tuesday, December 4, 2018

Most of the presentations at SABCS® focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.

Partial Breast Irradiation - Where Does It Stand?
Moderator: Richard Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX 

Partial breast irradiation: efficacy and patient selection
Charlotte Coles, MB ChB, MRCP, FRCR, PhD
University of Cambridge
Cambridge, UNITED KINGDOM

Cosmesis and QOL considerations
Timothy J. Whelan, BSc, BM, BCh, MSc, FRCPC
McMaster University
Hamilton, CANADA

Techniques and technical considerations
Frank A. Vicini, MD, FACR, FABS, FASTRO
MHP Radiation Oncology Institute
Farmington Hills, MI

BRCA 1/2: Beyond DNA Repair
Moderator: Ratna K. Vadlamudi, PhD
UT Health San Antonio
San Antonio, TX

BRCA2 and control of transcription: R-loop dynamics
Ashok Venkitaraman, PhD
MRC Cancer Unit
University of Cambridge
Cambridge, UNITED KINGDOM

Link between BRCA1 and Pol II pausing in mammary gland development and tumorigenesis
Rong Li, PhD
UT Health San Antonio
San Antonio, TX

BRCA1/2/3 and p53 in replication fork stability 
Katharina Schlacher, PhD
UT MD Anderson Cancer Center
Houston, TX

Updates in the Treatment of Triple Negative Breast Cancer
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Optimizing treatment of early stage triple negative breast cancer: Clinical challenges and new scientific horizons
Angela DeMichele, MD, MSCE
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Updates on immunotherapy for TNBC
Sylvia Adams, MD
NYU Langone Health
New York, NY

Triple negative breast cancer: Current and future directions in metastatic patients 
Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX

Translational Insights in Estrogen Receptor Signaling and Endocrine Resistance - Bench to Bedside
Moderator: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Recurrent ESR1 mutations activating mutations in breast cancer 
Rinath M. Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

Mining noncoding mutations for new drivers of development in ER alpha-positive breast cancer
Mathieu Lupien, PhD
Princess Margaret Cancer Centre
Toronto, CANADA

Blockade of estrogen signaling boosts antitumor immunity by inhibiting tumor-induced pathological myelopoiesis
Jose Conejo-Garcia, MD, PhD
H. Lee Moffitt Cancer Center
Tampa, FL

Metabolic Reprogramming in Breast Cancer
Moderator: Alexander Bishop, DPhil, BSc
Greehey Children's Cancer Research Institute
UT Health San Antonio
San Antonio, TX

Oxidative stress responses in cancer
Joan S. Brugge, PhD
Harvard Medical School
Boston, MA

PI3K in breast cancer, glutamine changes and methionine addiction
Alex Toker, PhD
Beth Israel Deaconess Medical Center 
Boston, MA

Systems approaches to attacking cancer vulnerabilities defined by metabolic, de-differentiation and genomic instability states
Thomas G. Graeber, PhD
University of California Los Angeles
Los Angeles, CA

Management of the Axilla After Neoadjuvant Therapy: Beyond the Clinical Trials
Moderator: Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Methods to minimize the false negative rate of sentinel lymph node surgery after neoadjuvant chemotherapy for node positive breast cancer
Judy C. Boughey, MD
Mayo Clinic
Rochester, MN

Practical approach to the axilla after neoadjuvant chemotherapy: What the clinical trials don't address
Andrea V. Barrio, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Indications for radiation treatments after neoadjuvant chemotherapy while awaiting the results of clinical trials  
Thomas A. Buchholz, MD
Scripps Health 
San Diego, CA

Twenty Years of Targeting HER2: Where Are We Now?
Moderator: Mothaffar F. Rimawi, MD
Baylor College of Medicine
Houston, TX

What is a HER2-positive in breast cancer in 2018?
Stuart J. Schnitt, MD
Dana-Farber Cancer Institute
Boston, MA

Early HER2-positive breast cancer: Doing more or less
Lisa A. Carey, MD
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Advanced HER2-positive breast cancer: Overcoming treatment resistance 
Mothaffar F. Rimawi, MD
Baylor College of Medicine 
Houston, TX

Insights and Controversies in Metastasis Biology
Moderator: Michael Lewis, PhD
Baylor College of Medicine
Houston, TX

The EMT and metastasis controversy: Where things stand in 2018
Heide L. Ford, PhD
University of Colorado School of Medicine
Aurora, CO

Breast cancer’s metastatic moment: How postpartum tissue involution facilitates progression
Pepper J. Schedin, PhD
Oregon Health & Science University Hospital
Portland, OR

Exosome-mediated stimulation of metastasis
Andy J. Minn, MD
University of Pennsylvania
Philadelphia, PA

Exposures Throughout the Lifecourse - New Data on the Environment, Hormones, and Alcohol
Moderator: Melissa L. Bondy, PhD
Baylor College of Medicine
Houston, TX

Windows of susceptibility across the lifecourse and breast cancer
Lawrence H. Kushi, ScD
Kaiser Permanente Northern California
Oakland, CA

Does breast cancer prevention need an 18th amendment? New evidence on alcohol and breast cancer
Mary Beth Terry, PhD
Columbia University
New York, NY

New data on hormones and risk of breast cancer
Susan E. Hankinson, ScD
University of Massachusetts
Amherst, MA

Late Recurrence in ER Positive Breast Cancer: Therapeutic Interventions and Biological Insights
Moderator: Matthew J. Ellis, MD, PhD
Baylor College of Medicine
Houston, TX

Tumor dormancy and recurrence
Lewis A. Chodosh, MD, PhD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Clinical and molecular profiles to identify who is at risk?
Mitchell Dowsett, PhD
Ralph Lauren Centre for Breast Cancer Research
London, UNITED KINGDOM

Late recurrence in ER-positive breast cancer
Julie R. Gralow, MD
University of Washington School of Medicine
Seattle, WA

Managing Lymphedema in 2018: Can We Forgo The Sleeve?
Moderator: Bhuvaneswari Ramaswamy, MBBS, MRCP
The Ohio State University
Columbus, OH

Current status of diagnosis, monitoring, and non-surgical management of lymphedema
Sarah A. McLaughlin, MD
Mayo Clinic 
Jacksonville, FL

Lymphedema management in 2018: Are we making any progress?
Babak J. Mehrara, MD
Memorial Sloan Kettering Cancer Center 
New York, NY

Microsurgical treatment of lymphedema
David W. Chang, MD, FACS
University of Chicago
Chicago, IL 

Contemporary Management of Breast Cancer Brain Metastases
Moderator: Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA

Tumor microenvironment that may predispose to brain mets
Patricia S. Steeg, PhD
National Cancer Institute
Bethesda, MA

Multidisciplinary management of breast cancer brain metastases
Christina I.Tsien, MD
Washington University School of Medicine
St. Louis, MO

Systemic therapy for breast cancer brain metastases
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA

Top

 



 

William L. McGuire Memorial Lecture

Hold That Scalpel! Using the Tumor to Determine the Treatment
Ian E. Smith, MD, FRCP, FRCPE
The Royal Marsden NHS Foundation Trust
London, UNITED KINGDOM

AACR Distinguished Lectureship in Breast Cancer Research

AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen®

Susan G. Komen® Brinker Award

Top


Neoadjuvant Endocrine Therapy: The Times They are A-Changing
Ingrid A. Mayer, MD, MSCI
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, TN

Breast Tumor Evolution and Intratumor Heterogeneity - Insights from Single Cell Genomics
Nicholas E. Navin, PhD
UT MD Anderson Cancer Center
Houston, TX

Top


Man vs. Machine: Now and in the Future
Moderator: Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX

Artificial intelligence for healthcare
Alan Karthikesalingam, MD, PhD
DeepMind
London, UNITED KINGDOM

Deep learning systems for reading mammograms and breast tomosynthesis
Nico Karssemeijer, PhD
Radboud University Medical Centre
Nijmegen, NETHERLANDS

Artificial intelligence to optimize the accuracy and predictiveness of breast cancer pathology
Andrew H. Beck, MD, PhD
PathAI
Cambridge, MA

Over and Under Treatment: The Bookends That Keep Us From Getting It Right For Each Patient
Moderator: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Overtreatment
Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Missed opportunities – The perils of under-treatment
Rachel A. Freedman, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

 

Top

 

 


Saturday, December 8, 2018

Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

Basic science
Robert Benezra, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Translational research
Andrew Tutt, FRCR, PhD
The Institute of Cancer Research
London, UNITED KINGDOM

Early stage breast cancer, Year In Review: Evolving paradigms  
Priyanka Sharma, MD
University of Kansas Medical Center
Westwood, KS

Metastatic breast cancer
Roisin M. Connolly, MBBCh, MD
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, MD

Top
 


Peering into Tumor-Microenvironment Interaction in Metastasis
Moderator: Yi Li, PhD
Baylor College of Medicine
Houston, TX

High resolution intravital imaging of the mechanism of how breast cancer initiates and sustains systemic dissemination
John Condeelis, PhD
Albert Einstein College of Medicine
Bronx, NY

Neutrophil extracellular traps promote breast cancer metastasis
Mikala Egeblad, PhD
Cold Spring Harbor Laboratory 
Cold Spring Harbor, NY

New insights into early-stage bone colonization of disseminated breast cancer cells
Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX

Top


Interplay Between Breast Cancer Targeted Therapies and the Immune System
Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

Modulation of anti-tumor immunity using CDK4/6 inhibitors 
Shom Goel, B Med Sci, MBBS, FRACP, PhD
Dana-Farber Cancer Institute
Boston, MA

BRCA1 and the immune system
Geoffrey Lindeman, BSc, MBBS, PhD, FRACP, FAHMS, FAA
Walter and Eliza Hall Institute of Medical Research
Parkville, AUSTRALIA

PI3K Pathway in Breast Cancer
Moderator: Carlos L. Arteaga, MD
UT Southwestern
Harold C. Simmons Cancer Center
Dallas, TX

    The complexity of targeting PI3K for cancer therapy
            Lewis C. Cantley, PhD
            The Sandra and Edward Meyer Cancer Center
            New York, NY

Clinical development of inhibitors of the P13K pathway
Cristina Saura Manich, MD, PhD
Vall d'Hebron University Hospital
Barcelona, SPAIN

Lessons learned from the development of P13K therapeutic inhibitors
Dejan Juric, MD
Massachusetts General Hospital
Boston, MA

 

Top


Cancer Genetics: Updates for Breast Cancer Care
Moderator: Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Polygenic risk scores for breast cancer: Ready or not?
D. Gareth Evans, FRCP, MD, MBBS
University of Manchester
Manchester, UNITED KINGDOM

Breast cancer genetic testing and results in diverse populations
Allison W. Kurian, MD, MSc
Stanford University School of Medicine
Stanford, CA

Moderate penetrance mutations: What to do?
Susan M. Domchek, MD
University of Pennsylvania
Philadelphia, PA

Top


Molecular Biology in Breast Oncology
Moderator: Carlos L. Arteaga, MD
UTSW Simmons Comprehensive Cancer
Harold C. Simmons Cancer Center
Dallas, TX

Novel targets in breast cancer: How to go about drugging them?
Lori Friedman, PhD
Genentech, Inc.
South San Francisco, CA

The breast tumor microenvironment: Clinical implications for checkpoint inhibitors
Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Circulating tumor DNA analysis to elucidate drug action & resistance
Nicholas Turner, PhD, FRCP
The Royal Marsden Hospital
London, UNITED KINGDOM

Molecular heterogeneity of TNBC: Biological implications
Samuel Aparicio, PhD
University of British Columbia
BC Cancer Agency
Vancouver, BC CANADA

Clinical Research
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Phase I clinical trials: Is there more than 3+3?
Susan G. Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX

Regulatory perspectives: Validation of molecular diagnostic assays
Reena Philip, PhD
US Food and Drug Administration
Silver Spring, MD

Incorporating patient reported outcomes and functional measures into clinical trials
Jennifer A. Ligibel, MD
Dana-Farber Cancer Institute
Boston, MA

Design of immunotherapeutic trials in breast cancer
Sherene Loi, MBBS (Hons), FRACP, PhD, FAHMS
Peter MacCallum Cancer Centre
Melbourne, AUSTRALIA

 

Top

CASE DISCUSSIONS

                                                                                                                       

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
              

Top

CAREER DEVELOPMENT FORUM NETWORKING SESSION FOR YOUNG INVESTIGATORS

                                                                                                                       

The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2018 SABCS®. Space in the workshop is limited. Preregistration is not required.                                                                                                                             



                                                                                                     
                                                                                                                      

Should all women with breast cancer and positive lymph nodes receive chemotherapy?
Chairman: Clifford A. Hudis, MD
American Society of Clinical Oncology
Alexandria, VA

Daniel Hayes, MD, FASCO, FACP
University of Michigan
Ann Arbor, MI

Harold Burstein, MD, PhD
Dana-Farber Cancer Institute
Boston, MA




Friday, December 7, 2018
                                                                                                                      

Will examine presentations at SABCS® and put them in context of clinical practice

Moderator: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Panel Members:

Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Debra Patt, MD, MPH
Texas Oncology
Austin, TX

Meredith M. Regan, ScD
Dana-Farber Cancer Institute
Boston, MA

Hope S. Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA 


Bárbara Segarra-Vázquez, DHSc
University of Puerto Rico
San Juan, PR

 

      

.

Top


PRELIMINARY SCHEDULE

Hours subject to change

Monday, December 3  Registration  12:00 PM-5:00 PM 
Tuesday, December 4 Registration 8:00 AM-7:00 PM
  Program (Workshops and Educational Sessions) 11:00 AM-7:00 PM
Wednesday, December 5 Registration 7:00 AM-5:15 PM
  Program (Main Program begins) 8:00 AM-7:00 PM
  Exhibits 11:00 AM-5:00 PM
Thursday, December 6 Registration 6:45 AM-5:15 PM
  Program 7:30 AM-7:00 PM
  Exhibits 11:00 AM-5:00 PM
Friday, December 7 Registration 6:45 AM-5:15 PM
  Program 7:30 AM-7:00 PM
  Exhibits 11:00 AM-5:00 PM
Saturday, December 8 Registration 6:45 AM-9:00 AM
  Program 7:30 AM-11:00 AM
Top